E2 ModerateModerate confidencePEM not requiredCross-SectionalPeer-reviewedMachine draft
Standard · 3 min
Neurocognitive screening in patients following SARS-CoV-2 infection: tools for triage.
Blackmon, Karen, Day, Gregory S, Powers, Harry Ross et al. · BMC neurology · 2022 · DOI
Quick Summary
Many people recovering from COVID-19 report trouble thinking clearly or remembering things. This study tested 102 COVID-19 patients (some who were hospitalized, some who weren't) within about 3-4 weeks of infection to see how common these cognitive problems really were and what might cause them. The researchers found that while most patients felt foggy-headed, people who had been hospitalized showed more measurable problems with memory and thinking speed than those who recovered at home.
Why It Matters
For patients experiencing long-term cognitive symptoms after COVID-19 (a condition that overlaps with ME/CFS symptoms), this study validates that objective cognitive testing—not just subjective complaints—should be used to diagnose and track brain function problems. Understanding whether psychiatric symptoms like anxiety and depression drive cognitive impairment, versus being consequences of it, is crucial for developing targeted treatments. The finding that hospitalized patients show different cognitive patterns than ambulatory ones suggests that severity and type of acute infection may influence post-viral cognitive sequelae, an important consideration for understanding post-viral ME/CFS mechanisms.
Observed Findings
27-40% of ambulatory patients self-reported cognitive impairment at 24±22 days post-infection
30% of hospitalized patients showed objective visual memory impairment versus 4% of ambulatory patients
41% of hospitalized patients demonstrated objective psychomotor speed deficits versus 15% of ambulatory patients
In ambulatory patients, objective cognitive performance correlated with anxiety, depression, fatigue, and pain
In hospitalized patients, no association was found between objective cognitive deficits and neuropsychiatric symptoms
Inferred Conclusions
Focal cognitive deficits are more common in hospitalized than ambulatory COVID-19 patients during early recovery
Objective neurocognitive measures reveal impairment not captured by subjective symptom reporting alone
Neuropsychiatric symptoms may contribute to cognitive impairment in less severely ill patients, but alternative mechanisms may drive deficits in hospitalized patients
Neurocognitive screening should be incorporated as a standard clinical and research endpoint in COVID-19 recovery protocols
Remaining Questions
Do cognitive deficits persist, improve, or worsen in the months and years following infection in either group?
What This Study Does Not Prove
This study does not establish whether cognitive impairment persists beyond the sub-acute recovery phase or whether it resolves with time. It cannot prove that anxiety, depression, and fatigue *cause* cognitive deficits in ambulatory patients—the association could be bidirectional or mediated by an unmeasured factor. The small sample size (particularly 26 hospitalized patients) limits generalizability, and the cross-sectional design cannot distinguish between pre-existing cognitive vulnerabilities and acute infection effects.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
What mechanisms underlie the discrepancy between subjective complaints and objective impairment, and do they differ by hospitalization status?
Do neuropsychiatric symptoms precede cognitive impairment in ambulatory patients, or do they develop secondarily to cognitive dysfunction?
What specific neurobiological mechanisms (viral persistence, inflammation, microvascular injury, mitochondrial dysfunction) drive cognitive impairment in severe versus mild COVID-19?